GSE119978 GSE180930 cisplatin 6 v 1 human dn (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE119978_GSE180930_cisplatin_6_v_1_human_dn.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE119978_GSE180930_cisplatin_6_v_1_human_dn.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE119978_GSE180930_cisplatin_6_v_1_human_dn.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE119978_GSE180930_cisplatin_6_v_1_human_dn.

Results found

Linked to

 

Label

Description

 

Gene

MIR4435-2 host gene

Gene

small nucleolar RNA host gene 3

Gene

NBPF member 8

Gene

small nucleolar RNA host gene 4

Gene

general transcription factor IIi pseudogene 4

Gene

dehydrogenase/reductase X-linked

Gene

small nucleolar RNA host gene 17

Gene

metastasis associated lung adenocarcinoma transcript 1

Gene

oligodendrocyte maturation-associated long intergenic non-coding RNA

Gene

synaptotagmin 15B


  • Gene

    small nucleolar RNA host gene 3



  • Gene

    small nucleolar RNA host gene 4


  • Gene

    general transcription factor IIi pseudogene 4


  • Gene

    dehydrogenase/reductase X-linked


  • Gene

    small nucleolar RNA host gene 17


  • Gene

    metastasis associated lung adenocarcinoma transcript 1


  • Gene

    oligodendrocyte maturation-associated long intergenic non-coding RNA


  • Gene

    synaptotagmin 15B

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.